A small molecule that selectively kills the pathogen causing sleeping sickness and Chagas disease has been developed by scientists from the Helmholtz Zentrum München, along with colleagues from the Technical University of Munich and the Ruhr University Bochum. The researchers first determined the parasite’s Achilles heel by using modern structural biology techniques and then developed an inhibitor with a perfect fit.
Prof. Dr. Michael Sattler, Director of the Institute of Structural Biology at the Helmholtz Zentrum München and Professor of Biomolecular NMR Spectroscopy at the Technical University of Munich, said:
“Until now, there have been only a few medications against trypanosomes. These drugs have many undesirable side effects, and first cases of resistance are already spreading. We primarily concentrated on the so-called PEX proteins, which have been under debate as potential targets for pharmacological interference for some time.”
Together with Dr. Grzegorz Popowicz, also of Helmholtz Zentrum München, and the group headed by Prof. Dr. Ralf Erdmann at Ruhr University Bochum, the research team sought new possibilities to deactivate the pathogen.
Trypanosomes get their name from the Greek trypano- (borer) and soma (body). The protozoan parasites are responsible for various diseases, particularly in Latin America and Africa, including Chagas disease and leishmaniases.
The best known example is probably sleeping sickness, which is caused by trypanosomes and transmitted by tsetse flies. In the end stage, patients suffer from uncontrollable sleep, which gave the sickness its name.
The PEX proteins play a crucial role in the function of the so-called glycosomes. These are small cell organelles that are important to maintain the parasite’s sugar metabolism.
“The idea was to prevent the interaction between two essential proteins, PEX14 and PEX5, and consequently to disrupt the trypanosome metabolism so effectively that the parasites cannot survive,” explains Grzegorz Popowicz.
At the Bavarian NMR Center, a joint research infrastructure of the Helmholtz Zentrum and TU München, the researchers therefore first used nuclear magnetic resonance (NMR) to investigate the structure of the two target proteins.
In the next step, the teams from Munich and Bochum used the thus determined spatial structure to optimize a substance that specifically binds to PEX14, thereby preventing the interaction with PEX5, which eventually kills the parasite. Grzegorz Popowicz describes it as,
“We more or less first measured the lock and then developed the right key for it.”
In the future, the researchers want to further advance these molecules using medicinal chemistry so that they can be tested in clinical studies and, eventually may be approved as drugs. They are also examining the extent to which the approach is suitable to kill other single-cell parasites that may depend on similar proteins.
One possibility could be to target the Leishmania parasite, said Popowicz.
Image: Structure of the interface of PEX14 and PEX5 (back) including the structure of the inhibitor (front). Credit: Dr. Grzegorz Popowicz, Helmholtz Zentrum München